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Size dependent effects of Gold 
Nanoparticles in ISO-induced 
Hyperthyroid Rats
Jingwen Zhang1, Yanbo Xue1, Yajuan Ni2, Feifei Ning1, Lijun Shang  3 & Aiqun Ma1
In this study, we applied different sizes of gold nanoparticles (Au-NPs) to isoproterenol (ISO)-induced 
hyperthyroid heart disease rats (HHD rats). Single dose of 5, 40, 100 nm Au-NPs were injected 
intravenously. Cardiac safety tests were evaluated by cardiac marker enzymes in serum and cardiac 
accumulation of Au-NPs were measured by ICP-MS. Our results showed that size-dependent cardiac 
effects of Au-NPs in ISO-induced hyperthyroid rats. 5 nm Au-NPs had some cardiac protective effect  
but little accumulation in heart, probably due to smaller size Au-NPs can adapt to whole body easily in 
vivo. Histological analysis and TUNEL staining showed that Au-NPs can induce pathological alterations 
including cardiac fibrosis, apoptosis in control groups, however they can protect HHD groups from 
these harmful effects. Furthermore, transmission electron microscopy and western blotting employed 
on H9C2 cells showed that autophagy presented in Au-NPs treated cells and that Au-NPs can decrease 
LC3 II turning to LC3 I and decrease APG7 and caspase 12 in the process in HHD groups, while opposite 
effects on control groups were presented, which could be an adaptive inflammation reacts. As there are 
few animal studies about using nanoparticles in the treatment of heart disease, our in vivo and in vitro 
studies would provide valuable information before they can be considered for clinical use in general.
Hyperthyroid heart disease is characterized as high cardiac output and dynamic ECG changes. It is usually caused 
by high sensitivity of the heart to catechomale. Long-term untreated hyperthyroid heart disease can lead to heart 
failure, which is hard to treat and have poor prognosis. Currently there is no effective methods to treat end-stage 
heart failure, therefore finding a new way to target the heart in the first place is still a best prevention.
Gold Nanoparticles (Au-NPs) have been widely employed in biomedical fields, such as imaging and bio-
logical labeling1, cancer treatment2,3, and their toxic effects on the liver, lung, kidney, brain and reproductive 
system have been studied widely4–8. There are also growing interests to investigate its effects on the heart, but 
all present studies vary from the type of Au-NPs used, the different heart disease conditions and animal models 
employed, and the administration periods and routes etc.9–14. In general, the accumulation of Au-NPs in the heart 
is size-dependent when administered intravenously15 but the conclusion varied from case to case. Therefore, there 
are still great needs to have detailed studies on the effects of Au-NPs on the heart and its related diseases.
In this study, we used different sizes of 5, 40, 100 nm Au-NPs to test their effects on both normal and 
ISO-induced hyperthyroid rats by measuring ECG and UCG parameters and cardiac enzyme in serum. The 
accumulation distributions of Au-NPs in the heart was also measured by inductively coupled plasma mass spec-
trometry (ICP-MS). Furthermore, Histological analysis and TUNEL staining were used to determine pathological 
alterations including cardiac fibrosis and apoptosis. It is known that autophagy can trigger apoptosis and lead 
to cell death, but it can also present cardiac protective mechanism under several basal conditions. Therefore, 
transmission electron microscopy and western blotting were both employed on H9C2 cells (a sub-clone derived 
from embryonic rat heart tissue) in vitro to evaluate the effects of autophagy and to explore the possible mecha-
nism of the effects of Au-NPs. We found that Au-NPs can induce protective effects on HHD groups by decreas-
ing their autophagy levels, but increase autophagy in control groups, which could be an adaptive inflammation 
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reacts. However, they can induce cardiac toxicity and change the cardiac function if their uses are not properly 
controlled. These effects of Au-NPs on heart can bring altered histological structure in the first place before they 
can change the cardiac function. As there are few animal studies of using nanoparticles in the treatment of heart 
disease, our in vivo and in vitro studies would provide valuable information before they can be considered for 
clinical use in general.
Results
A week Isoproterenol injection produce a hyperthyroid heart disease rat model. Hyperthyroid 
disease is characterized by typical symptoms of cardiac arrhythmia, including nodal tachycardia, premature atrial 
contraction, paroxysmal tachycardia, ventricular flutter and ventricular fibrillation. Ventricular fibrillation is the 
most common change among them. Hyperthyroid disease inducing to heart failure is associated with several 
reasons, including (1) Hyperthyroid can induce beta receptor hyperfunction in the heart. Longer time of heavy 
heart work load can then lead to heart enlargement and cardiac output increase; (2) Heart oxygen consumption 
increase and cause energy dysmetabolism; (3) Tachyarrhythmia, typically ventricular fibrillation, can induce car-
diac output decrease.
Typical ECG changes of hyperthyroid heart disease include but not exclude: (1) left ventricular hypertrophy; 
(2) ST-T segment changes: pathological decline of ST-T segment and T wave changes (decline, bidirectional and 
inversion); (3) Hyperthyroidism P wave: it is known that 26% of hyperthyroid disease patients has abnormal P 
wave changes; (4) P-Q segment changes: 1.7~4.6% of hyperthyroid patients has P-Q segment increase; (5) High T 
wave: 14% of severe hyperthyroid patients has high T wave; and 6) Q-T segment: Q-T segment increase is more 
common than decrease.
We used a large dose of ISO (20 mg/kg/mL) intraperitoneal injection in SD rats for 7 days, and this can lead 
to the classic changes of hyperthyroid heart disease in electrocardiogram and measurements (Fig. 1, Table 1). 
There was no observation of significant changes on animal behaviors and body weights (Supplementary Fig. 1). 
These were evidenced by measured parameters compared to the normal control, such as raised q wave amplitude, 
high peak of P wave morphology (indicated by P wave amplitude/P wave duration), increased P wave ampli-
tude, decreased P wave duration, and increased QTc interval (Table 1). All these changes indicated that ISO can 
induce the classic electrocardiogram phenomenon of hyperthyroid heart disease, which has high risk of cardiac 
arrhythmia.
The further results of Echocardiography showed that hyperthyroid heart disease (HHD) groups had signif-
icant increase of cardiac output (CO) and atrial enlargement (left atrial longitudinal diameter), which were in 
accordance with the changes of hyperthyroid, heart disease on heart function and structure parameters. ECG 
analysis showed that HHD groups had ventricular high voltage (indicating left ventricular hypertrophy), biodi-
rectional P wave or ventricular flutter, QT segment increase (Table 2). All the above ECG changes were in accord-
ance with hyperthyroid heart disease. These results indicated that a large dose of ISO can successfully mimick the 
pathophysiological state of hyperthyroid heart disease. At the same time, these results indirectly showed that the 
high sensitivity of catecholamine on the heart was the primary reason of hyperthyroid heart disease at least in the 
early stage, while the toxicity of thyroxine on the heart ranked the second reason.
Figure 1. ISO-induced electrocardiogram changes mimicked hyperthyroid heart disease: changed P wave 
morphology and increased Q wave. The size of Au-NPs had no effect ECG morphology in normal rat hearts. 
Au-NPs protected against ISO-induced P wave or Q wave changes but may induce the increase in R wave 
amplitude.
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Au-NPs can reduce ISO induced cardiac toxicity. We further tested the cardiac effects of different sizes 
of Au-NPs on both control and ISO-induced hyperthyroid heart disease rats. After sedation, three leads were con-
nected to rats’ three limbs separately. All electrocardiogram parameters were measured using BL420E recording 
system and listed in Table 1.
We recorded P-R segment duration and corrected QT interval in normal and HHD groups. These parameters 
can reflect heart conduction function and are correspondence to sinoatrial node conduction and ventricular 
repolarization function separately. We applied Au-NPs to ISO-induced rats and the results showed that they 
can affect P-R segment duration and corrected QT interval evaluation (Table 1). Au-NPs had minor effect on 
heart conduction function, except for 40 nm Au-NPs, which decreased QTc in normal group (Table 1), indicating 
40 nm Au-NPs may interfere with ventricular repolarization process in normal rats.
The effects of Au-NPs on atrial depolarization were measured by P wave duration, P wave amplitude and their 
ratio. 5 and 40 nm Au-NPs can effectively improve P wave morphology by decreasing P wave amplitude (Table 1) 
in HHD groups, indicating 5 and 40 nm Au-NPs may interfere with atrial depolarization in hyperthyroid heart 
disease rats.
The effects of Au-NPs on ventricular depolarization were measured by q wave amplitude and QRS duration. 
Au-NPs had no effect on q wave in both control and hyperthyroid heart disease groups. QRS duration was also 
unchanged in HHD groups, except 40 nm-AuNPs can decrease QRS duration in HHD groups (Table 1), indicat-
ing 40 nm Au-NPs interfere with ventricular depolarization in HHD groups.
The effects of Au-NPs on ventricular depolarization were measured by R wave and S wave amplitude and 
their ratio. Au-NPs had minor effect on R and S wave amplitude in control groups, except 5 nm Au-NPs, which 
decreased R wave amplitude in normal groups (Table 1). All sizes of Au-NPs decreased ISO-induced S wave 
increasing in HHD groups (Table 1). Since 100 nm Au-NPs tended to increase R wave (Ctrl-100 nm: 0.42 ± 0.02 
vs HHD-100 nm: 0.65 ± 0.08 mV, P < 0.05, n = 5), together with decreased S wave, 100 nm-AuNPs treated HHD 
rats presented left ventricular high voltage amplitude. These results indicated that 100 nm Au-NPs is more likely 
to induce ventricular hypertrophy, while 5 and 40 nm Au-NPs are less likely compared with 100 nm Au-NPs, at 
least in HHD groups.
The effects of Au-NPs on ventricular repolarization function were compared by T wave amplitude and 
duration and their ratio. Au-NPs had no effect on T wave parameters in control groups (Table 1). Since T wave 
duration increased in HHD control compared to the normal control (Table 1), and T wave amplitude tended to 
decrease in HHD groups, T wave morphology in HHD groups was flatter than those in the control groups (Fig. 2, 
Table 1). This phenomenon was the classic changes of hyperthyroid heart disease, which further confirmed that 
Group 0 nm 5 nm 40 nm 100 nm
P-R segment duration (ms)
Ctrl 44.10 ± 1.79 44.67 ± 0.95 49.67 ± 1.41 44.00 ± 2.70
HHD 39.00 ± 3.35 36.33 ± 2.32 40.29 ± 1.67 41.60 ± 1.17
QTc (ms)
Ctrl 130.12 ± 4.47 120.30 ± 11.77 113.11 ± 7.07* 129.22 ± 11.86
HHD 151.02 ± 11.28§ 142.06 ± 12.15 140.27 ± 5.96 149.82 ± 8.51
P wave duration (ms)
Ctrl 16.20 ± 0.63 19.67 ± 2.22* 16.83 ± 0.98 15.60 ± 2.20
HHD 12.00 ± 0.55§§ 12.17 ± 0.83 13.29 ± 0.75 12.60 ± 1.29
P wave amplitude(mV)
Ctrl 0.057 ± 0.00396 0.0567 ± 0.0042 0.07 ± 0.00966 0.058 ± 0.01068
HHD 0.1120 ± 0.01356§§§ 0.0667 ± 0.00989* 0.0643 ± 0.01251* 0.08 ± 0.00837
P (mV)/P(ms)
Ctrl 0.0036 ± 0.00030 0.0032 ± 0.00052 0.0043 ± 0.00066 0.0041 ± 0.00099
HHD 0.0096 ± 0.00145§§§ 0.0056 ± 0.00085* 0.0051 ± 0.00123* 0.0065 ± 0.00074
Q wave amplitude(mV)
Ctrl 0.0210 ± 0.00504 0.0217 ± 0.00543 0.0167 ± 0.00422 0.018 ± 0.002
HHD 0.054 ± 0.02227§ 0.0333 ± 0.00558 0.0240 ± 0.00245 0.05 ± 0.01304
QRS duration(ms)
Ctrl 25.70 ± 3.89 22.17 ± 1.33 21.17 ± 0.60 21.60 ± 0.60
HHD 24.40 ± 2.89 22.33 ± 1.65 19.14 ± 1.01* 20.60 ± 1.57
R wave amplitude(mV)
Ctrl 0.567 ± 0.04387 0.3433 ± 0.07877* 0.4483 ± 0.07414 0.42 ± 0.02
HHD 0.42 ± 0.12946 0.5067 ± 0.05548 0.4671 ± 0.078 0.65 ± 0.08
S wave amplitude(mV)
Ctrl 0.138 ± 0.02235 0.2533 ± 0.08019 0.1517 ± 0.04826 0.274 ± 0.05446*
HHD 0.286 ± 0.07305§ 0.1217 ± 0.03928* 0.1186 ± 0.04554* 0.04 ± 0.03808*
R(mV)/S(mV)
Ctrl 4.91 ± 0.68 2.46 ± 0.79 8.66 ± 4.45 2.60 ± 1.16
HHD 2.11 ± 0.86 7.45 ± 2.71 17.16 ± 10.74 19.76 ± 10.39
T wave amplitude(mV)
Ctrl 0.075 ± 0.02001 0.0533 ± 0.02472 0.0617 ± 0.01327 0.082 ± 0.02417
HHD 0.03 ± 0.03 0.0233 ± 0.01783 0.0157 ± 0.0173 0.044 ± 0.004
T wave duration(ms)
Ctrl 23.67 ± 2.96 28.67 ± 7.88 30.33 ± 1.86 28.67 ± 11.92
HHD 36.33 ± 3.18§ 18.67 ± 2.19** 31.33 ± 10.48 31.67 ± 3.76
T (mV)/T(ms)
Ctrl 0.0021 ± 0.00069 0.0015 ± 0.00121 0.0021 ± 0.00037 0.0017 ± 0.00093
HHD 0.0012 ± 0.00138 0.0011 ± 0.00104 0.0004 ± 0.00052 0.0014 ± 0.00015
Table 1. Electrocardiogram parameters measured in both control and hyperthyroid heart disease rats treated 
with different sizes of Au-NPs. Intra-group significance, *P < 0.05, **P < 0.01, ***P < 0.001; Inter-group group 
significance, §P < 0.05, §§P < 0.01, §§§P < 0.001; n = 6.
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animal modeling creation was successful. 5 nm-AuNPs decreased T wave in HHD groups which was increased by 
ISO induction in HHD control groups. These results indicated that 5 nm Au-NPs may protect ventricular repo-
larization duration from increasing in hyperthyroid heart disease groups.
From the evaluation of the above-mentioned electrocardiogram parameters, it was suggested that 5 nm could 
lead to protective effect in HHD groups, 40 nm and 100 nm have cardiac toxic potential in HHD groups.
Au-NPs can affect cardiac function and heart morphology in both normal and hyperthyroid rats. 
We used echocardiography to evaluate the effects of Au-NPs on both control and ISO-induced hyperthyroid heart 
disease rats. The representative images of echocardiography treated with Au-NPs in both groups were shown in 
Fig. 2. All relevant parameters were measured and listed in Table 2.
From echocardiography measurement (Table 2), we found that fractional shortening (FS%), cardiac output 
(CO), left atrial longitudinal diameter and heart rate (BP) were all increased in ISO-induced hyperthyroid heart 
disease groups compared with the control groups, which indicated the typical hyperdynamic circulatory state 
of hyperthyroid heart disease in these rats. The increase in left atrial longitudinal diameter also indicated that 
ISO injection produced the trend for atrial enlargement (Ctrl-0 nm: 4.52 ± 0.15 vs HHD-0 nm: 4.99 ± 0.28 mm, 
P > 0.05, n = 6), which is common in long-term hyperthyroidism. All these results indicated large dose of ISO 
injection for a week successfully created the hyperthyroid heart disease animal model.
The effects of Au-NPs on cardiac function were measured by ejection fraction (EF%), fractional shorten-
ing (FS%) and cardiac output (CO, L/min). These parameters are main indicators for heart functions with the 
EF% as the key one. The decreased value in EF% indicates decreased heart function. Our results showed that 
40 nm-AuNPs decreased EF%, and FS% in both control and hyperthyroid groups, but 5 nm and 100 nm Au-NPs 
had no significant effects on them (Table 2). All sizes of Au-NPs decreased CO in control groups (Table 2), but 
only 5 nm Au-NPs decreased CO in HHD groups. These results indicated that 40 nm Au-NPs reduced cardiac 
function in HHD groups.
The effects of Au-NPs on atrial size were evaluated by left atrial cross-sectional and longitudinal diam-
eters. Au-NPs were unable to decrease atrial enlargement in HHD groups. 5 nm-AuNPs decreased left atrial 
cross-sectional diameter in control groups, indicating the decreased atrial size; while 40 nm Au-NPs increased left 
Group 0 nm 5 nm 40 nm 100 nm
EF%
Ctrl 82.62 ± 1.33 80.15 ± 2.87 76.27 ± 2.17* 82.16 ± 3.63
HHD 85.45 ± 0.76 83.33 ± 2.8 79.58 ± 1.90* 82.40 ± 3.23
FS%
Ctrl 46.21 ± 1.36 43.92 ± 2.92 39.62 ± 2.02* 46.44 ± 3.82
HHD 49.18 ± 0.87§ 47.4 ± 2.8 43.2 ± 1.95* 46.6 ± 3.82
CO (L/min)
Ctrl 0.17 ± 0.01 0.11 ± 0.01** 0.10 ± 0.01*** 0.13 ± 0.01*
HHD 0.19 ± 0.01§ 0.18 ± 0.02** 0.19 ± 0.02 0.19 ± 0.02
LVEDd (mm)
Ctrl 5.89 ± 0.13 5.36 ± 0.26 5.57 ± 0.2 5.77 ± 0.17
HHD 6.08 ± 0.25 5.98 ± 0.17 6.16 ± 0.24 5.95 ± 0.25
LVESd (mm)
Ctrl 3.18 ± 0.14 3.05 ± 0.28 3.36 ± 0.14 3.11 ± 0.31
HHD 3.10 ± 0.16 3.14 ± 0.2 3.51 ± 0.22 3.19 ± 0.29
EDV (mL)
Ctrl 0.48 ± 0.03 0.39 ± 0.04 0.42 ± 0.04 0.46 ± 0.04
HHD 0.54 ± 0.06 0.5 ± 0.04 0.55 ± 0.06 0.51 ± 0.07
ESV (mL)
Ctrl 0.09 ± 0.01 0.08 ± 0.02 0.1 ± 0.01 0.09 ± 0.02
HHD 0.08 ± 0.01 0.08 ± 0.02 0.12 ± 0.02 0.09 ± 0.02
IVSd (mm)
Ctrl 1.31 ± 0.05 1.43 ± 0.08 1.38 ± 0.05 1.19 ± 0.27
HHD 1.22 ± 0.13 1.24 ± 0.04* 1.29 ± 0.05 1.25 ± 0.08
IVSs (mm)
Ctrl 1.97 ± 0.09 1.79 ± 0.1 1.95 ± 0.12 1.97 ± 0.13
HHD 1.81 ± 0.12 1.80 ± 0.12 1.82 ± 0.08 1.74 ± 0.12
LVPWd (mm)
Ctrl 1.40 ± 0.03 1.40 ± 0.06 1.37 ± 0.04 1.46 ± 0.06
HHD 1.30 ± 0.11 1.36 ± 0.05 1.35 ± 0.07 1.30 ± 0.09
LVPWs (mm)
Ctrl 2.09 ± 0.08 1.96 ± 0.11 2.06 ± 0.13 2.29 ± 0.09*
HHD 2.01 ± 0.11 2.00 ± 0.12 1.96 ± 0.11 1.98 ± 0.13
Left atrial cross-sectional (mm)
Ctrl 4.1 ± 0.14 3.58 ± 0.16* 4.16 ± 0.16 4.28 ± 0.13
HHD 4.06 ± 0.22 3.85 ± 0.15 4.57 ± 0.07* 4.37 ± 0.34
Left atrial longitudinal (mm)
Ctrl 4.52 ± 0.15 4.40 ± 0.18 4.90 ± 0.18 4.17 ± 0.1*
HHD 4.99 ± 0.28 4.72 ± 0.28 5.17 ± 0.30 5.03 ± 0.35*
BP (btm)
Ctrl 406.24 ± 9.59 381.11 ± 19.73 340.51 ± 22.64* 345.48 ± 31.76*
HHD 432.50 ± 9.62§ 452.25 ± 10.29 441.24 ± 6.26 440.86 ± 10.36
Table 2. Effects of Au-NPs on cardiac function and heart morphology measured by Echocardiography in 
normal and ISO-induced hyperthyroid heart disease groups. Intra-group significance, *P < 0.05, **P < 0.01, 
***P < 0.001; Inter-group group significance, §P < 0.05, §§P < 0.01, §§§P < 0.001; n = 6.
www.nature.com/scientificreports/
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atrial cross-sectional diameter in control groups, indicating atrial enlargement (Table 2). These results indicated 
that 5 nm may has cardiac protective effect while 40 nm may be cardiac toxic.
The effects of Au-NPs on left ventricular dimension and volume were tested by measuring left ventricular 
end-diastolic diameter (LVEDd), left ventricular end-systolic diameter (LVEDs), End-diastolic volume (EDV) 
and End-systolic volume (ESV). Au-NPs intervention had no effect on left ventricular dimension and volume in 
normal groups for 7 days period. 40 nm-AuNPs had the potential to increase LVEDs and to enlarge ESV in HHD 
groups (Table 2), which was in accordance with the results of electrocardiogram. These results indicated that 
40 nm may cause cardiac muscle injury in HHD groups.
The effects of Au-NPs on ventricular thickness were measured by Interventricular Septum Diameter at the end 
of systole (IVSs) and Interventricular Septum Diameter at the end of diastole (IVSd), Left Ventricular Posterior 
Wall diameter at the end of diastole (LVPWd) and Left Ventricular Posterior Wall diameter at the end of systole 
(LVPWs). 100 nm-AuNPs increased LVPWs in control groups (Table 2), indicating 100-AuNPs can exert cardiac 
hypertrophy in normal hearts.
From the above-mentioned results, we concluded that 5 nm-AuNPs had cardiac protective potential by reduc-
ing atrial dimension. 40 nm-AuNPs had apparent cardiac toxic by decreasing cardiac function in both groups. 
100 nm-AuNPs had cardiac toxic effect by causing cardiac hypertrophy in control groups. These results were 
basically in accordance with all measured parameters from electrocardiogram.
Different Au-NPs exert dynamic changes on lipid profile and cardiac marker enzyme. We 
tested the effects of Au-NPs on blood lipids in both groups by measuring aspartate transaminase (AST), (total 
cholesterol) CHOI and (triglyceride) TG. 100 nm-AuNPs increased AST in HHD groups (Table 3), indicating 
100 nm may cause liver function damage in HHD groups. 5 nm and 40 nm Au-NPs decreased TG in HHD groups 
(Table 3), showing that 5 and 40 nm had protective potential toward coronary heart diseases.
We further evaluated the effect of Au-NPs on lipid protein and apolipoprotein in both groups. HDL-C (high 
density lipoprotein-cholesterol), LDL-C (low density lipoprotein-cholesterol), APOA (apolipoprotein A) and 
APOB (apolipoprotein B) were measured. 40 nm-AuNPs decreased LDL-C in HHD groups (Table 3), indicating 
40 nm had cardiac protective effect against coronary heart disease. 5 nm and 40 nm Au-NPs increased APOB level 
in control groups (Table 3), indicating that 5 and 40 nm Au-NPs had cardiac protective potential toward coronary 
heart disease. This was in agreeable with one clinical study16.
We also tested the effect of Au-NPs on general cardiac marker enzyme, such as Lactate dehydrogenase (LDH) 
and hydroxybutyrate dehydrogenase (HBDH). The increased HBDH normally occurs in acute heart attack, and 
the ratio of LDH/HBDH is valuable for diagnose the liver and heart diseases. 40 nm-AuNPs decreased LDH 
(Table 3) and HBDH in control groups, indicating 40 nm had cardiac protective potential against cardiac muscle 
injury.
CK-MB (Creatine Kinase Isoenzyme) is the isoenzyme of CK (Creatine kinase) specifically expressed in hearts 
and skeletal muscle, and they are usually used in clinic to diagnose acute heart infarction. CK-MB will normally 
increase during the first several days after heart injury, and then CK-MB will decrease after the window period17. 
Figure 2. Representative images of echocardiography of rats treated with Au- NPs in normal (A) and ISO-
induced hyperthyroid heart disease groups (B). (A) Representative images of echocardiography of rats treated 
with Au-NPs in normal groups; (B) Representative images of echocardiography of rats treated with Au-NPs in 
ISO-induced hyperthyroid heart disease groups.
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Therefore, we evaluated the effects of Au-NPs on the heart by this specific cardiac marker enzyme. CK-MB level 
increased in HHD groups compared with the control groups (Table 3), confirming again the successful of the 
ISO-induced hyperthyroid heart disease animal model. 5 nm-AuNPs increased CK in both groups but decreased 
CK’s specific cardiac isoenzyme CK-MB in control groups. 40 nm-AuNPs decreased CK-MB in control and HHD 
groups (Table 3). Combining these results, it was clearly shown that 5 nm Au-NPs had no cardiac toxic effect. 
Since 40 nm-AuNPs has been shown to be cardiac toxic by electrocardiogram and echocardiography detections, 
the abnormally decreased CK-MB by 40 nm did not indicate that 40 nm had cardiac protection effect, rather than 
that it may cause cardiac toxicity. It might be possible that CK-MB may have increased immediately after 40 nm 
Au-NPs injection but decreased during following 7 days. The increased CK value also needs to be checked to 
exclude the possibility of skeletal muscle injury.
We concluded that 5 and 40 nm Au-NPs had cardiac protective effect against coronary heart diseases, since 
they can decrease harmful lipid or lipid proteins. 5 nm had cardiac protective effect towards cardiac injury 
(CK-MB decreased in normal groups), and 40 nm Au-NPs may have cardiac toxicity towards cardiac injury which 
were in accordance with electrocardiogram and echocardiography results. 100 nm Au-NPs processed toxic effect 
against liver function (decreased AST in HHD groups), while 100 nm Au-NPs didn’t have any effect on CK or 
CK-MB, indicating that100 nm Au-NPs showed no cardiac protective effects.
Size-dependent Au-NPs accumulation in the heart is also dependent on the state of disease. 
To explore the reasons for the different effects of Au-NPs on control and HHD rats, we tested the accumula-
tion of Au-NPs in both control and hyperthyroid heart disease rats. Au-NPs accumulation turned to be animal 
state dependent. 100 nm Au-NPs accumulated more in the hearts of the HHD groups than those in control rats 
(Ctrl-100 nm: 16.79 ± 6.16 vs HHD-100 nm: 401 ± 163.41 ng/g tissue, P < 0.05, n = 4, Fig. 3A). Different sizes of 
Au-NPs also accumulated differently in the HHD hearts. 40 nm-AuNPs accumulated less than 100 nm-AuNPs in 
the hearts of the HHD groups (HHD-40 nm:12 ± 6.37 vs HHD-100 nm: 401 ± 163.41 ng/g heart tissue, P < 0.05, 
n = 4, Fig. 3A).
Au-NPs markedly exaggerate cardiac fibrosis and apoptosis in normal rats but decrease histo-
logical alteration in ISO-induced hyperthyroid heart disease groups in size-dependent manner. 
We further tested if there are histological alterations by Au-NPS in both normal and HHD rats. HE, 
hematoxylin-eosin staining (magnification, x20) staining was performed to determine general histological alter-
ations in control and ISO-induced hyperthyroid heart disease groups (Fig. 4). Red part represented muscle cyto-
plasm while blue part demonstrated nucleus in HE stains. The histological heart alterations induced by Au-NPs 
were size-dependent with 40 nm Au-NPs demonstrated prominent congested dilated blood vessels in control 
groups, while for HHD groups, the pathological changes were decreased with few lymphocytic infiltrate and less 
disturbed muscle fascicles when combined with 5 nm and 100 nm Au-NPs application (n = 4 to 6).
Group 0 nm 5 nm 40 nm 100 nm
AST(U/L)
Ctrl 261.00 ± 63.61 354.8 ± 77.08 450.33 ± 153.05 301.33 ± 49.70
HHD 154.75 ± 29.56 168.8 ± 27.92 157.4 ± 12.93* 288.33 ± 56.02*
CHO1(mmol/L)
Ctrl 1.09 ± 0.04 1.14 ± 0.10 1.09 ± 0.10 1.03 ± 0.09
HHD 1.27 ± 0.21 1.10 ± 0.02 0.96 ± 0.09 0.97 ± 0.06
TG(mmol/L)
Ctrl 0.83 ± 0.20 0.60 ± 0.09 0.7 ± 0.20 0.39 ± 0.03
HHD 1.08 ± 0.14 0.67 ± 0.07* 0.54 ± 0.14* 0.81 ± 0.06
HDL-C(mmol/L)
Ctrl 0.34 ± 0.03 0.36 ± 0.03 0.4 ± 0.04 0.33 ± 0.005
HHD 0.31 ± 0.005 0.4 ± 0.03 0.32 ± 0.04 0.33 ± 0.03
LDL-C(mmol/L)
Ctrl 0.34 ± 0.04 0.29 ± 0.04 0.27 ± 0.04 0.3 ± 0.04
HHD 0.45 ± 0.07 0.3 ± 0.02 0.26 ± 0.02* 0.33 ± 0.05
APOA(g/L)
Ctrl 0.00067 ± 0.001 0.00025 ± 0.00027 0.00125 ± 0.001 0.0002 ± 0.00024
HHD 0.0005 ± 0.0015 0.00026 ± 0.00037 0.0005 ± 0.001 0.00028 ± 0.00028
APOB(g/L)
Ctrl 0.0067 ± 0.00033 0.0142 ± 0.00217* 0.017 ± 0.001** 0.007 ± 0.001
HHD 0.007 ± 0.002 0.007 ± 0.00071 0.0065 ± 0.00065 0.006 ± 0.001
LDH(U/L)
Ctrl 875.33 ± 73.44 770.25 ± 94.82 412.0 ± 50.0* 392.0 ± 93.74*
HHD 1504.0 ± 267.0 1591.5 ± 365.0 904.0 ± 40.1 1449.5 ± 9.5
HBDH(U/L)
Ctrl 337.33 ± 18.32 270.5 ± 27.67 185.0 ± 23.0* 374.0 ± 45.0**
HHD 501.0 ± 122.0 540.0 ± 123.37 316.25 ± 10.36 474.0 ± 39.0
CK(U/L)
Ctrl 1061.25 ± 16.38 2027.0 ± 62.91* 911.0 ± 41.85 1022.0 ± 16.0
HHD 748.25 ± 111.57 1751.0 ± 316.15* 780.8 ± 180.83 1045.33 ± 145.83
CKMB(U/L)
Ctrl 683.0 ± 60.34 462.75 ± 41.84* 324.5 ± 24.5* 1108.5 ± 88.5
HHD 955.0 ± 70.0§ 1191.75 ± 206.77 619.75 ± 36.77** 952.5 ± 3.5
Table 3. Effects of Au-NPs on cardiac marker enzyme measured in normal and ISO-induced hyperthyroid 
heart disease groups. *P < 0.05, **P < 0.01, ***P < 0.001; n = 6.
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MASSON (magnification, x20) staining was performed to determine cardiac fibrosis of the hearts in two 
groups treated with different sizes of Au-NPs (Fig. 5). Quantification results showed that there was more car-
diac fibrosis in the hearts of HHD groups than those in control groups, (Ctrl-0 nm: 2 ± 1.2% vs HHD-0 nm: 
100 ± 1.0%, P < 0.001, n = 6, Fig. 3B). Within control groups, 5 nm Au-NPs (Ctrl-0 nm: 2 ± 1.2% vs Ctrl-5 nm: 
10 ± 1.0%, P < 0.001, n = 6), 40 nm Au-NPs (Ctrl-0 nm: 2 ± 1.2% vs Ctrl-40 nm: 35 ± 3.0%, P < 0.001, n = 6) and 
100 nm-Au-NPs (Ctrl-0 nm: 2 ± 1.2% vs Ctrl-100 nm: 15 ± 2.3%, P < 0.001, n = 6) caused more fibrosis than 
normal control which was treated with 0 nm Au-NPs (Fig. 3B). Within HHD groups however, 5 nm Au-NPs 
(HHD-0 nm: 100 ± 1.0% vs HHD-5 nm: 80 ± 5.0%, P < 0.01, n = 6) and 100 nm Au-NPs (HHD-0 nm: 100 ± 1.0% 
vs HHD-100 nm: 90 ± 7.0%, P < 0.001, n = 6) caused less fibrosis than the HHD control which was treated with 
0 nm Au-NPs, while 40 nm Au-NPs caused more (HHD-0 nm: 100 ± 1.0% vs HHD-40 nm: 120 ± 4.0%, P < 0.01, 
n = 6). (Fig. 3B). *P < 0.05; **P < 0.01, ***P < 0.001.
TUNEL (magnification, x40) staining was performed to determine cardiac apoptosis of the hearts in two 
groups treated with different sizes of Au-NPs (Fig. 6). Quantification results show that more cardiac apoptosis 
was observed in the hearts of HHD groups than those in control groups (Ctrl-0 nm: 6 ± 1.1% vs HHD-0 nm: 
Figure 3. Accumulation of Au-NPs in the heart in control and ISO-induced hyperthyroid heart disease groups. 
(A) Accumulation of Au in the heart in both control and hyperthyroid heart disease groups (scale bar = 1 μm). 
100 nm Au-NPs accumulated more in the hearts in HHD groups than in normal groups (Ctrl-100 nm: 
16.79 ± 6.16 vs HHD-100 nm: 401 ± 163.41 ng/g heart tissue, P < 0.05, n = 4). 40 nm-AuNPs accumulated less 
than 100 nm-Au-NPs in the hearts in HHD groups (HHD-40 nm:12 ± 6.37 vs HHD-100 nm: 401 ± 163.41 ng/g 
tissue, P < 0.05, n = 4). (B) MASSON (magnification, x20) staining. More cardiac fibrosis was quantified in the 
hearts of HHD groups than those in control groups, (Ctrl-0 nm: 2 ± 1.2% vs HHD-0 nm: 100 ± 1.0%, P < 0.001, 
n = 6). Within control groups, 5 nm Au-NPs (Ctrl-0 nm: 2 ± 1.2% vs Ctrl-5 nm: 10 ± 1.0%, P < 0.001, n = 6), 
40 nm Au-NPs (Ctrl-0 nm: 2 ± 1.2% vs Ctrl-40 nm: 35 ± 3.0%, P < 0.001, n = 6) and 100 nm-Au-NPs (Ctrl-0 nm: 
2 ± 1.2% vs Ctrl-100 nm: 15 ± 2.3%, P < 0.001, n = 6) caused more fibrosis than normal control which was 
treated with 0 nm Au-NPs. Within HHD groups however, 5 nm Au-NPs (HHD-0 nm: 100 ± 1.0% vs HHD-5 nm: 
80 ± 5.0%, P < 0.01, n = 6) and 100 nm Au-NPs (HHD-0 nm: 100 ± 1.0% vs HHD-100 nm: 90 ± 7.0%, P < 0.001, 
n = 6) caused less fibrosis than the HHD control which was treated with 0 nm Au-NPs. While  40 nm Au-NPs 
caused more (HHD-0 nm: 100 ± 1.0% vs HHD-40 nm: 120 ± 4.0%, P < 0.01, n = 6). *P < 0.05; **P < 0.01, 
***P < 0.001. (C) TUNEL (magnification, x40) staining. More cardiac apoptosis was quantified in the hearts of 
HHD groups than those in control groups (Ctrl-0 nm: 6 ± 1.1% vs HHD-0 nm: 100 ± 3.1%, P < 0.001, n = 6). 
5 nm AuNPs (Ctrl-0 nm: 6 ± 1.1% vs Ctrl-5 nm: 20 ± 2.0%, P < 0.001, n = 6), 40 nm AuNPs (Ctrl-0 nm: 6 ± 1.1% 
vs Ctrl-40 nm: 50 ± 5.0%, P < 0.001, n = 6) and 100 nm-AuNPs (Ctrl-0 nm: 6 ± 1.1% vs Ctrl-100 nm: 40 ± 3.4%, 
P < 0.001, n = 6) caused more apoptosis than Ctrl treated with 0 nm Au-NPs. In HHD group however, 100 nm 
AuNPs (HHD-0 nm: 100 ± 3.1% vs HHD-100 nm: 85 ± 5.3%, P < 0.01, n = 6) caused less apoptotic volume than 
HHD treated with 0 nm Au-NPs. While 40 nm Au-NPs caused more (HHD-0 nm: 100 ± 3.1% vs HHD-40 nm: 
110 ± 4.6%, P < 0.001, n = 6). (n = 4 to ≈6). *P < 0.05; **P < 0.01, ***P < 0.001. (D) Transmission electron 
microscopy observation H9c2 cells were seeded in T25 (1 × 106 cells/mL) and cultured for 24 hr with different 
sizes of Au-NPs at a concentration of 10 µg/mL. Representative upper image (scale bar = 1 μm) showed that 
100 nm Au-NPs undergone typical autophagy process in the cells. Lower image showed that (scale bar = 0.6 μm) 
Au-NPs were enwrapped in a phagocytic vesicle and they were going to fuse with lysosome. (E) Representative 
images of Western blotting showing the expression levels of APG7, caspase 3, LC3A/B and GAPDH. 
Quantification of APG7, caspase 3, LC3A/B levels indicated that 40 and 100 nm Au-NPs cause autophagy in 
control group while 5,40 and 100 nm Au-NPs elevated autophagy in HHD groups (n = 6). *P < 0.05.
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100 ± 3.1%, P < 0.001, n = 6) (Fig. 3C). Within control groups, 5 nm Au-NPs (Ctrl-0 nm: 6 ± 1.1% vs Ctrl-5 nm: 
20 ± 2.0%, P < 0.001, n = 6), 40 nm Au-NPs (Ctrl-0 nm: 6 ± 1.1% vs Ctrl-40 nm: 50 ± 5.0%, P < 0.001, n = 6) and 
100 nm-Au-NPs (Ctrl-0 nm: 6 ± 1.1% vs Ctrl-100 nm: 40 ± 3.4%, P < 0.001, n = 6) caused more apoptosis than 
those in control group which was treated with 0 nm Au-NPs (Fig. 3C). Within HHD groups however, 100 nm 
Au-NPs (HHD-0 nm: 100 ± 3.1% vs HHD-100 nm: 85 ± 5.3%, P < 0.01, n = 6) caused less apoptotic volume than 
those in HHD control which was treated with 0 nm Au-NPs, while 40 nm Au-NPs caused more (HHD-0 nm: 
100 ± 3.1% vs HHD-40 nm: 110 ± 4.6%, P < 0.001, n = 6). (Fig. 3C). *P < 0.05; **P < 0.01, ***P < 0.001.
Autophagy in rat cardiomyocytes treated with Au-NPs and its possible mechanism. To explore 
the possible mechanism of the effects of Au-NPs, we carried out transmission electron microscopy observation 
on rat cardiomyocytes H9c2 cells in vitro. H9c2 cells were seeded in T25 (1 × 106 cells/mL) and cultured for 
Figure 4. The effects of Au-NPs on cardiac histological changes pronounced by HE stain in normal and ISO-
induced hyperthyroid heart disease groups. HE (magnification, x20) staining was performed to determine 
general histological alterations in control and ISO-induced hyperthyroid heart disease groups. Red part 
represented muscle cytoplasm while blue part demonstrated nucleus in HE stains. The histological heart 
alterations induced by Au-NPs were size-dependent with 40 nm AuNPs demonstrated prominent congested 
dilated blood vessels in control groups, while for HHD groups, the pathological changes were decreased with 
few lymphocytic infiltrate and less disturbed muscle fascicles when combined with 5 nm and 100 nm application 
(n = 6).
Figure 5. The effects of Au-NPs on cardiac left ventricular collagen volume pronounced by Masson stain 
in normal and ISO-induced hyperthyroid heart disease groups. Masson (magnification, x20) staining was 
performed to determine cardiac fibrosis in control and ISO-induced hyperthyroid heart disease groups. Red 
part represented muscle tissue while blue part demonstrated fibrosis in Masson stain. The fibrosis volume 
induced by Au-NPs was size-dependent with 40 nm AuNPs induced more effects in control groups, while for 
ISO-induced hyperthyroid heart disease groups, more pronounced fibrosis volume was caused but decreased 
when combined with 5 nm and 100 nm AuNPs application (n = 6).
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24 hr with different sizes of Au-NPs at a concentration of 10 µg/mL. Representative upper image (Fig. 3D, scale 
bar = 1 μm) showed that 100 nm Au-NPs undergone typical autophagy process in the cells. Lower image showed 
that (Fig. 3D, scale bar = 0.6 μm) Au-NPs were enwrapped in a phagocytic vesicle and they were going to fuse 
with lysosome.
Western blotting results (Fig. 3E) showed that the expression levels of APG7, caspase 3, LC3A/B and GAPDH. 
Quantification of APG7, caspase 3, LC3A/B levels indicated that 40 and 100 nm Au-NPs caused autophagy in 
control groups while 5, 40 and 100 nm Au-NPs elevated autophagy in HHD groups (n = 6). *P < 0.05.
Discussion
End-stage of hyperthyroid heart disease and many other heart diseases is heart failure, which has high morbidity 
and mortality and poor diagnosis. Currently most patients with heart diseases need to take various drugs for their 
life time. Since the diverse side-effects of those drugs, the patients’ compliance to treatment are low, and this leads 
to high re-hospitalization. NPs have gained positive results in phase III cancer treatment due to its good targeting 
and delivery ability, but there are only limited studies of using Au-NPs in the treatment of heart diseases in vitro. 
It is also known that the characteristics of nanoparticles can change dramatically between in vivo and in vitro. 
Therefore in vivo studies are fundamentally needed before Au-NPs application can be considered in clinical use.
In this study, firstly we created an ISO-induced hyperthyroid heart disease animal model. After 7 days of sin-
gle dose intraperitoneal injection in normal rats and we created ISO-induced hyperthyroid rats, we then tested 
cardiac effects of different sizes of Au-NPs by measuring various parameters from electrocardiogram, echocardi-
ography and cardiac marker enzymes in vivo/in vitro.
Hyperthyroid heart disease is generated by the effect of excess thyroid hormones on thyroid hormone recep-
tors which is important for control of heart rate18. The high sensitivity of this heart rate controlling receptor of 
thyroid hormones or excessive high level of thyroid hormones can cause excessive fast heart rate. That is the 
mechanism or pathophysiological of hyperthyroid heart disease. If heart rate remains fast for a longer time, for 
example several days or weeks, the subject will present with the typical manifestation of hyperthyroid heart dis-
ease, such as high cardiac output and typical atrial ECG changes as described in our Echocardiography and ECG 
results (Figs 1, 2). Our hyperthyroid heart disease model was produced by consecutive isoproterenol injection for 
a week. It is well known that isoproterenol can target specifically of the ß1-receptor which mainly expressed in 
the heart, and the activation of this receptor can cause heart rate increase. Although there are other studies using 
levothyroxine to induce hyperthyroid heart disease model, but it usually takes 6 to 7 weeks, much longer than 
our 1-week period19, and those studies mainly focused on the endocrine secretion rather than on hyperthyroid 
heart disease. Therefore, we used ISO to induce the hyperthyroid model rather than the traditional levothyroxine 
method, and all measured parameters proved that our model was successful and was good to be used to test the 
effects of Au-NPs in hyperthyroid heart disease.
Our results showed that Au-NPs of 40 nm showed cardiac toxicity in both control and HHD groups, that 
100 nm Au-NPs showed cardiac toxicity mainly in control groups, and that 5 nm Au-NPs showed no cardiac 
toxicity. 100 nm Au-NPs accumulated more in hyperthyroid rat hearts than in the normal rat hearts. These results 
indicated that the cardiac protective effect of NPs does not entirely rely on the accumulation of Au in hearts.
We recorded electrocardiogram and echocardiography 7 days after single dose of 10 ug of Au-NPs admin-
istration. Our results showed that 40 nm-AuNPs reduced cardiac function in both normal and HHD groups. 
Figure 6. The effects of Au-NPs on cardiac left ventricular apoptotic volume by TUNEL analysis in normal and 
ISO-induced hyperthyroid heart disease groups. Representative images of the TUNEL analysis from the control 
and ISO-induced hyperthyroid heart disease groups were demonstrated (magnification, x40). Brown nucleus 
represented apoptotic cells while blue nucleus demonstrated normal cells in TUNEL stain. The apoptotic 
volume induced by Au-NPs was size-dependent with 40 nm AuNPs  induced more effects in control groups, 
while for ISO-induced hyperthyroid heart disease groups, more pronounced apoptotic volume was caused but 
decreased when combined with 100 nm AuNPs application (n = 6).
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In addition, 40 nm-AuNPs caused atrial enlargement in HHD groups. On the other hand, 100 nm-AuNPs 
increased LVPWs in control groups, indicating 100-AuNPs can cause cardiac hypertrophy in normal hearts, 
while 5 nm-AuNPs had cardiac protective potential by reducing atrial dimension.
There is no report about cardiac toxicity by single dose of Au-NPs administration. In our study, single dose 
administration of 40 nm and 100 nm Au-NPs can induce cardiac toxicity after 7 days while 5 nm has no cardiac 
toxicity. Therefore, we concluded that the cardiac toxicity is dependent on the size of Au-NPs, and smaller size 
of Au-NPs may have little cardiac toxicity in vivo. Yang et al. used 13 nm Au-NPs to treat ISO (5 mg/kg)-induced 
cardiac hypertrophy rats and showed that Au-NPs induced no cardiac protective and toxicity effect20. Another 
study21 showed that the repeated administration of 10 nm-AuNPs via tail veins for 14 consecutive days can induce 
cardiac hypertrophy in normal mice, but this effect can be reversed during washout period. Taken together that 
5 nm has no cardiac toxicity in our study, we inferred that Au-NPs ranging from 10 nm to 20 nm would be possi-
ble candidate to be used in treating heart disease. We suspect that small size Au-NPs might have cardiac toxicity if 
administrated by repeated dose with much longer exposure time22,23. Further studies are needed to confirm this. 
Other small sizes of Au-NPs, either <5 nm or any between 5 to 40 nm also need to be chosen to carry out same 
test.
Moreover, in biochemical test of blood taken from rats of both groups, we found that CK-MB was decreased in 
both 40 nm-AuNPs treated control groups and HHD groups. Electrocardiography results has already showed that 
40 nm Au-NPs have cardiac toxicity, and the CK-MB were only detectable after several days of cardiac damage. 
Therefore 40 nm-AuNPs had cardiac toxicity, but this effect may not be detected by cardiac enzyme parameters 7 
days after Au-NPs were injected. However, Ferreira et al. showed that Au-NPs (10 and 30 nm) can lead to oxida-
tive damage several weeks after the acute administration for a single intraperitoneal injection24, therefore more 
persistent and specific cardiac marker enzyme need to be developed to delicately measure the exact toxicity of 
Au-NPs on hearts.
Secondly, we studied the relationship between toxicity effects and distribution and accumulation of Au-NPs 
in normal and diseased hearts. In our study, different sizes of Au-NPs were injected intravenously in rats. After 7 
days of ISO intervention in HHD groups, we took hearts from both groups to measure the concentration of Au by 
inductively coupled plasma-mass spectrometry (ICP-MS). Our results showed that in control groups without ISO 
injection, 40 nm-AuNPs showed the highest Au accumulation, while 100 nm ranked the second, 5 nm the least. 
These results are similar to one previous study, in which ICP-MS detection showed that small Au-NPs (13 nm) 
accumulated higher levels in heart compared with 4 nm and 100 nm after 7 days injection25,26.
In HHD groups, 100 nm-AuNPs accumulated most in hearts, while 40 nm ranked the second and 5 nm the 
least. It is reported that larger NPs can accumulate in diseased heart better than in normal heart. Lundy et al. 
found that 20–200 nm diameter nanoparticles are optimal for passive targeting of the injured left ventricle imme-
diately following cardiac ischemia-reperfusion injury in mice27. This is in accordance with our study which 
showed that 100 nm can target the hearts of HHD groups better than the smaller sizes. However, our data also 
showed that 100 nm-AuNPs can induce cardiac hypertrophy in hyperthyroid heart disease rats. Therefore, cau-
tions are needed when applying larger size NPs.
Finally, our study showed that 5 nm-AuNPs decreased left atrial cross-sectional diameter in control groups, 
which means that 5 nm-AuNPs may process cardiac protective potential to decrease atrial enlargement. Previous 
studies28 reported that ultra-small NPs are cardiac toxic, since they can block hERG channels in vitro, which 
means they have high risk of cardiac arrhythmia. However, further in vivo analysis showed that high dose of 
50 mg/kg 1.4 nm AnNPs did not block the channel and give a trace of heart arrhythmia. NPs can form a protein 
corona when confronted with protein-containing solutions like serum or full blood29,30, in which process will 
lead to the enlargement of the diameter of NPs. Since there is no in vivo study of smaller NPs size than 10 nm in 
treating heart disease, our results confirmed that although 5 nm-AuNPs didn’t accumulate as much as 40 nm and 
100 nm Au-NPs did in hearts, they had cardiac protective potential.
Histological analysis and TUNEL staining showed that Au-NPs can induce pathological alterations includ-
ing cardiac fibrosis, apoptosis in control group, however they can protect HHD groups from these harmful 
effects. Further transmission electron microscopy using H9C2 cells (a sub-clone derived from embryonic rat 
heart tissue) in vitro showed that autophagy presented in Au-NPs treated cells. In this case, Western blotting 
focusing on autophagy process in Au-NPs treated mouse were conducted to evaluate the effect of autophagy. 
The results showed that Au-NPs can suppress (microtubule-associated protein 1 light chain 3) LC3 I turning to 
LC3 II which is a standard phenomenon of autophagy31,32, and decrease autophagy-associated protein APG733 
and apoptosis-associated protein caspase 1234 in the process in HHD groups but presented opposite effects on 
control groups. It is known that autophagy can trigger apoptosis and lead to cell death, but it can also play cardiac 
beneficial role in the heart35. Therefore, we conclude that Au-NPs can induce protective effect on HHD groups by 
decreasing their autophagy level, but increase autophagy in control groups, which could be an adaptive inflam-
mation reacts. However, they can induce cardiac toxicity36 and change the cardiac function if their uses are not 
properly controlled. These effects of Au-NPs on heart can bring altered histological structure in the first place 
before they can change the cardiac function.
Au-NPs are known to have antioxidant potential in treating disease15. Most of intracellular reactive oxygen 
species (ROS) are generated as by-products of mitochondrial bioenergetics. Excess ROS production in heart mus-
cle is one of the mechanism and indicator for heart disease progression37. Au-NPs might exert its cardiac effects 
through changing the level of ROS production. We also observed that Au-NPs were involved with autophagy 
when they are entering rat heart muscle cells in vitro. It is known that autophagy can either induce cell survive or 
cell death. Under certain circumstances, autophagy constitutes a stress adaptation that avoids cell death (and sup-
presses apoptosis), whereas in other cellular settings, it constitutes an alternative cell-death pathway34. Therefore, 
it is possible that Au-NPs can change the state of cells from autophagy to apoptosis or vice versa. Further studies 
are needed to evaluate these possible mechanisms.
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In conclusion, our study showed that effects of Au-NPs on heart is size dependent. This might be linked to 
their size-dependent accumulation and distribution in hearts. The larger sizes of Au-NPs (more than 40 nm) 
are more likely to have cardiac toxicity effect. Thus, we recommend using smaller size of Au-NPs (<40 nm) in 
the treatment of the heart diseases. Moreover, although 5 nm didn’t accumulate in hearts as much as larger sizes 
in both normal and diseased hearts, it induced cardiac protective potential otherwise. The protective effect of 
Au-NPs need to be carefully monitored in relevant heart disease state before its effective clinical use.
As there are few animal studies about using nanoparticles in the treatment of heart disease, our in vivo and in 
vitro studies would provide valuable information before they can be considered for clinical use in general.
Materials and Methods
Gold nanoparticles. Au-NPs of different sizes (5, 40, 100 nm) were purchased from sigma. (Code: 752568, 
741981, 797758). All Au-NPs used in this study were in PBS solution at a concentration of 0.1 mM. The mean size 
and morphology of these Au-NPs were evaluated from transmission electron microscope (TEM) as we did before, 
and they were on within the range of product specification (data not shown).
Animals. Fifty-six healthy 6–7 weeks old, weight between 250–270 g male Sprague-Dawley (SD) rats were 
obtained from the Laboratory Animal Center of Xi’an Jiaotong University. The use of animal was approved by 
Xi’an Jiaotong University Ethics Committee (NO: XJTULAC2017-703).
Animals were randomly divided into 8 groups, 4 groups were 0, 5, 40, 100 nm Au-NPs treated control groups 
and another 4 groups were 0, 5, 40, 100 nm Au-NPs treated hyperthyroid heart disease (HHD) groups. The hyper-
thyroid heart disease groups were achieved by intraperitoneal injection with ISO (20 mg/kg/mL) from day 0 daily 
for 7 days. The 5, 40 and 100 nm Au-NPs were administered intravenously from caudal vein with dose of 0.1 mM 
for 500 µL per rat (that is 10 µg of Au-NPs per rat) at day 0 for all groups. The normal control group (0 nm Au-NPs 
groups) were injected with normal saline solution (0.9% concentration) with the same amount as ISO treated 
groups. The initial injections were carried out together at day 0, then the injection was kept at same time each day, 
therefore the interval time was 24 hrs.
The rats were maintained with standard laboratory rodent diet pellets and housed in humidity and 
temperature-controlled ventilated cages on a 12 h day/night cycle. All experiments were conducted in accordance 
with the guidelines approved by Laboratory Animal Care Committee (License No: 7-703).
Echocardiography. The rats were sedated with 10% chloral hydrate with dosage of 0.3 mL/per 100 g body 
weight through intraperitoneal injection before recording. Echocardiographic examinations were performed 
on an IE33 system (Philips, Eindhoven, Netherlands). Cardiac hemodynamics was evaluated as we previously 
described29. Cardiac function parameters such as left ventricular fractional shortening (LVFS), ejection fraction 
(EF) and cardiac output (CO) were recorded. The parameters evaluating the heart structure, including inter-
ventricular septum thickness at the end of systole (IVSTs), and interventricular septem thickness at the end of 
diastore (IVSTd) were also recorded.
Electrocardiogram. Animal sedation is the same as above for echocardiography. Electrocardiogram was 
assessed as we described previously35. Electrocardiogram parameters were recorded using BL-420 biological and 
functional experimental system (Tai Meng, LinYin, Chengdu). All data were analyzed with BL-New Century 
software (Tai Meng).
Serum parameters measurement. 5 mL of blood were taken from abdominal aorta on day 7 from each 
animal, and serum were obtained. Normal standard clinical parameters were evaluated by Hitachi LST008 auto-
matic biochemical analyzer (Japan) at the Clinical Laboratory Department of First Affiliated Hospital of Xi’an 
Jiaotong University. Lipid profile were measured with aspartate aminotransferase (AST), CHOI (total choles-
terol), TG (triglyceride), HDL-C (high density lipoprotein), LDL-C (low density lipoprotein), APOA (apolipo-
protein A) and APOB (apolipoprotein B). Cardiac enzyme markers including LDH (lactate dehydrogenase), 
HBDH (hydroxybutyrate dehydrogenase), CK (creatine phosphokinase), CK-MB (Creatine Kinase Isoenzyme) 
were also evaluated.
ICP-MS measurement. 7 days after single intravenously injection of 10 ug of different sizes of Au-NPs on 
day 0, animals are sedated as the same as above. Hearts were excised by thoracotomy as described previously36. 
The process of ICP-MS test was carried out as described previously25. Briefly, high concentration of HNO3 was 
used to digest the hearts. Then HNO3 solutions containing hearts were evaporated. Finally, 2% of HNO3 was used 
to dilute the remains to a 10 ml stock. ICP-MS was used here to evaluate the accumulation of Au in the stock.
Histological Analysis. For histological analysis, hearts were arrested with a 10% potassium chloride solu-
tion at end diastole and then fixed in 4% paraformaldehyde. Fixed hearts were embedded in paraffin and cut 
transversely into 5-μm sections. Serial heart sections were stained with hematoxylin-eosin or wheat germ agglu-
tinin (No. W11261; Invitrogen) to measure myocyte cross-sectional areas. The degree of collagen deposition 
was detected by a Masson kit (No. 017756; Promega). The degree of apoptosis was detected by a TUNEL kit (No. 
ab206386; Abcam). Images were analyzed using a quantitative digital image analysis system (Image-Pro Plus 6.0).
Western blot analysis. Antibodies against APG7 (No. 8558), LC3A/B (No. 12741), caspase-3 (No. 9662) 
and GAPDH (No. 2118) were purchased from Cell Signaling Technology (Boston, MA), and horseradish 
peroxidase-conjugated anti-rabbit IgG and anti-mouse IgG were purchased from Abcam (Cambridge, MA). 
Proteins were detected using Western blot analysis as described previously24. Cellular proteins were extracted 
according to the manufacturer’s instructions (Santa Cruz, CA). Equal amount of proteins were separated on a 
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10% SDS-PAGE gel and transferred onto a PVDF membrane (Millipore,MA), which was then incubated with 
primary antibodies and then with secondary antibodies. The membrane was developed, and protein signals were 
detected using chemiluminescence. Image acquisition tools and image processing software packages used was 
Quantity One (provided by Bio-Rad Technology).
H9c2 cell culture. The rat cardiomyocytes cell line was kindly provided by Jianjun Mu from Xi’an Jiaotong 
University and cultured as previously described37. Briefly, the cells were maintained in DMEM (Hyclone, GE 
healthcare, USA) supplemented with 10% FBS (Gibco), 100 U/mL penicillin, and 100 µg/mL streptomycin solu-
tion (Hyclone, GE healthcare, USA), and then incubated at 37 °C in a 5% CO2 humidified atmosphere.
Transmission electron microscopy observation. H9c2 cells were seeded in T25 (1 × 106 cells/mL) and 
cultured for 24 hr with different sizes of Au-NPs at a concentration of 10 µg/mL. H9c2 cells were then digested by 
0.25% Trysin (Gibco) and harvested by centrifuging at the speed of 1000 rpm for 3 min. The samples were fixed in 
2.5% glutaraldehyde followed by 1% perosmic acid and dehydrated in gradual ethanol series. Ultrathin sections 
(800 nm, thickness) were cut and double-stained with uranyl acetate and lead citrate. The ultra-structures were 
observed using a Transmission electron microscopy (TEM, HITACHI-H7650, Tokyo, Japan). The sample layer to 
quantify the intracellular accumulation of Au-NPs was not stained in order to avoid the interference of dye lead 
and these images were magnified to 4000 times. The sample layer to locate the intracellular Au-NPs were stained 
with lead dye in order to find out the interaction of Au-NPs with cytoplasmic organoids of rat cardiomyocytes and 
these images were magnified to 50,000 times.
Statistics. All data were expressed as the mean ± the standard error of the mean (S.E.M). A one-way ANOVA 
or two-tailed Student’s t-test was used to determine statistical significance between the control and test groups. A 
P-value of 0.05 or less was considered significant.
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